BSH 2022 | Treatment approaches for patients with R/R DLBCL: UK perspective
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses treatment pathways and decision-making in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the UK. Dr Osborne first highlights the importance of looking at whether a patient is fit enough for gemcitabine, dexamethasone, cisplatin (GDP) for first-line treatment. Following this, Dr Osborne explains the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients who are not fit for chemotherapy. To conclude, Dr Osborne then discusses treatment options for patients who are not fit for CAR-T or high-dose chemotherapy, and how second-line decisions can affect third-line treatment options. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
